Mr. Ken d'Entremont reports

HEALTH CANADA ACCEPTS FOR REVIEW MEDEXUS'S NEW DRUG SUBMISSION FOR TOPICAL TERBINAFINE

Medexus Pharmaceuticals Inc.'s new drug submission (NDS) for terbinafine hydrochloride nail lacquer, to treat fungal nail infections, has been accepted by Health Canada for review.

"Health Canada's commitment to review our NDS brings us a step closer to making topical terbinafine a viable treatment option for Canadians," said Richard Labelle, Medexus's general manager, Canadian operations. "Topical terbinafine is an excellent strategic fit for our leading allergy/dermatology business, and we look forward to putting our institutional knowledge to work as we target a commercial launch in the first half of calendar year 2025."

Topical terbinafine has been widely used in other markets to treat fungal nail infections. Medexus's NDS for topical terbinafine seeks Health Canada approval for a distinctive once-a-week treatment regimen. If and when approved, the product will enter the Canadian topical fungicides market that is estimated to be $88-million on an annual basis.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy and dermatology.

We seek Safe Harbor.